Antitachycardia Pacemakers in Congenital Heart Disease
dc.contributor.author | Kamp, Anna N. | en_US |
dc.contributor.author | LaPage, Martin J. | en_US |
dc.contributor.author | Serwer, Gerald A. | en_US |
dc.contributor.author | Dick, Macdonald | en_US |
dc.contributor.author | Bradley, David J. | en_US |
dc.date.accessioned | 2015-05-04T20:36:54Z | |
dc.date.available | 2016-05-10T20:26:28Z | en |
dc.date.issued | 2015-03 | en_US |
dc.identifier.citation | Kamp, Anna N.; LaPage, Martin J.; Serwer, Gerald A.; Dick, Macdonald; Bradley, David J. (2015). "Antitachycardia Pacemakers in Congenital Heart Disease." Congenital Heart Disease (2): 180-184. | en_US |
dc.identifier.issn | 1747-079X | en_US |
dc.identifier.issn | 1747-0803 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/111221 | |
dc.description.abstract | BackgroundMany patients with congenital heart disease (CHD) acquire rhythm abnormalities related to their repair, most commonly intraatrial reentrant tachycardia (IART). Treatment of IART in CHD is often multifaceted, and may include medication, ablation, and pacing. Evidence regarding the use of antitachycardia pacing therapies is limited.ObjectiveThe aim of the study is to define the use and efficacy of antitachycardia pacing in patients with CHD at a single center.ResultsEighty implants were performed on 72 patients between 2000 and 2010. Follow‐up data of more than 3 months were available for 56 patients; median follow‐up time was 2.8 years. Twenty (36%) patients received successful antitachycardia pacing at a median 1.3 years postimplant. For those patients with IART after implant, antitachycardia pacing was successful in 57%. Patients with two‐ventricle repairs were more likely to have successful antitachycardia pacing than those with one‐ventricle palliation (45% vs. 17%, P = .04). Patients with documented IART had more successful antitachycardia pacing than those with no documented atrial tachycardia prior to implant (46% vs. 7%, P = .006). Early complications of antitachycardia pacemaker implant occurred in six patients (11%); late complications after implant occurred in three patients (5.6%). Of the initial 72 patients implanted, there were six deaths (8%).ConclusionsAntitachycardia pacing therapies were successful in the majority of CHD patients who had IART after implant. Patients without documented atrial tachycardia prior to implant were unlikely to require or receive successful therapy from antitachycardia pacemaker. Those patients postatrial switch procedure who had documented IART prior to implant had the highest incidence of successful antitachycardia pacing therapies. Antitachycardia pacemaker implantation is an adjunct to the management of IART in CHD patients, but may not benefit patients who have not yet demonstrated IART. | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Antitachycardia Pacemakers | en_US |
dc.subject.other | Atrial Tachycardia | en_US |
dc.subject.other | Intraatrial Reentrant Tachycardia | en_US |
dc.subject.other | Congenital Heart Disease | en_US |
dc.title | Antitachycardia Pacemakers in Congenital Heart Disease | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/111221/1/chd12230.pdf | |
dc.identifier.doi | 10.1111/chd.12230 | en_US |
dc.identifier.source | Congenital Heart Disease | en_US |
dc.identifier.citedreference | Walsh EP, Cecchin F. Arrhythmias in adult patients with congenital heart disease. Circulation. 2007; 115: 534 – 545. | en_US |
dc.identifier.citedreference | Kannankeril PJ, Fish FA. Management of intra‐atrial reentrant tachycardia. Curr Opin Cardiol. 2005; 20: 89 – 93. | en_US |
dc.identifier.citedreference | Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device‐based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008; 51: e1 – e62. | en_US |
dc.identifier.citedreference | Drago F, Silvetti MS, Grutter G, De Santis A. Long term management of atrial arrhythmias in young patients with sick sinus syndrome undergoing early operation to correct congenital heart disease. Europace. 2006; 8: 488 – 494. | en_US |
dc.identifier.citedreference | Stephenson E, Casavant D, Tuzi J, et al. Efficacy of atrial antitachycardia pacing using the Medtronic AT500 pacemaker in patients with congenital heart disease. Am J Cardiol. 2003; 92: 871 – 876. | en_US |
dc.identifier.citedreference | Tsao S, Deal BJ, Backer CL, Ward K, Franklin WH, Mavroudis C. Device management of arrhythmias after Fontan conversion. J Thorac Cardiovasc Surg. 2009; 138: 937 – 940. | en_US |
dc.identifier.citedreference | Weipert J, Noebauer C, Schreiber C, et al. Occurrence and management of atrial arrhythmia after long‐term Fontan circulation. J Thorac Cardiovasc Surg. 2004; 127: 457 – 464. | en_US |
dc.identifier.citedreference | Schuster P, Faerestrand S, Ohm OJ. Device treatment of atrial tachycardia—minor additional effect of repeating pacing sequences. Int J Cardiol. 2005; 104: 10 – 14. | en_US |
dc.identifier.citedreference | Gulizia M, Mangiameli S, Orazi S, et al. Randomized comparison between Ramp and Burst+ atrial antitachycardia pacing therapies in patients suffering from sinus node disease and atrial fibrillation and implanted with a DDDRP device. Europace. 2006; 8: 465 – 473. | en_US |
dc.identifier.citedreference | Ricci R, Santini M, Padeletti L, et al. Atrial tachyarrhythmia recurrence temporal patterns in bradycardia patients implanted with antitachycardia pacemakers. J Cardiovasc Electrophysiol. 2004; 15: 44 – 51. | en_US |
dc.identifier.citedreference | Smerup M, Hjertholm T, Johnsen S, et al. Pacemaker implantation after congenital heart surgery: risk and prognosis in a population‐based follow‐up study. Eur J Cardiothorac Surg. 2005; 28: 61 – 68. | en_US |
dc.identifier.citedreference | Fortescue E, Berul C, Cecchin F, Walsh E, Triedman J, Aexander M. Patient, procedural, and hardware factos associated with pacemaker lead failures in pediatrics and congenital heart disease. Heart Rhythm. 2004; 1: 150 – 159. | en_US |
dc.identifier.citedreference | McLeod CJ, Asirvatham SJ, Warnes CA, Ammash NM. Device therapy for arrhythmia management in adults with congenital heart disease. Expert Rev Med Devices. 2010; 7: 519 – 527. | en_US |
dc.identifier.citedreference | Villain E. Indications for pacing in patients with congenital heart disease. Pacing Clin Electrophysiol. 2008; 31 ( suppl 1 ): S17 – S20. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.